Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by TD Cowen

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “hold” rating reiterated by analysts at TD Cowen in a research report issued on Friday, Benzinga reports.

A number of other research analysts also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday. Jefferies Financial Group restated a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Royal Bank of Canada reduced their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.07.

Marinus Pharmaceuticals Trading Up 36.2 %

MRNS stock traded up $0.11 during trading on Friday, reaching $0.40. The stock had a trading volume of 39,681,971 shares, compared to its average volume of 1,484,509. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The stock’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.67. The firm has a market cap of $22.21 million, a PE ratio of -0.15 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The firm had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same period in the prior year, the company posted ($0.61) EPS. On average, research analysts anticipate that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $28,000. SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $34,000. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $64,000. Finally, Values First Advisors Inc. lifted its stake in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares during the last quarter. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.